Advanced Proteome Therapeutics Stock Price To Book
| APTCF Stock | USD 0.0002 0.00 0.00% |
Advanced Proteome Therapeutics fundamentals help investors to digest information that contributes to Advanced Proteome's financial success or failures. It also enables traders to predict the movement of Advanced Pink Sheet. The fundamental analysis module provides a way to measure Advanced Proteome's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Advanced Proteome pink sheet.
Advanced |
Advanced Proteome Therapeutics Company Price To Book Analysis
Advanced Proteome's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Advanced Proteome Price To Book | 4.92 X |
Most of Advanced Proteome's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Advanced Proteome Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, Advanced Proteome Therapeutics has a Price To Book of 4.9209 times. This is 80.84% lower than that of the Biotechnology sector and 18.53% lower than that of the Health Care industry. The price to book for all United States stocks is 48.26% higher than that of the company.
Advanced Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Advanced Proteome's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Advanced Proteome could also be used in its relative valuation, which is a method of valuing Advanced Proteome by comparing valuation metrics of similar companies.Advanced Proteome is currently under evaluation in price to book category among its peers.
Advanced Fundamentals
| Return On Asset | -1.07 | |||
| Current Valuation | 660.53 K | |||
| Shares Outstanding | 41.13 M | |||
| Shares Owned By Insiders | 10.53 % | |||
| Price To Earning | 2.98 X | |||
| Price To Book | 4.92 X | |||
| Gross Profit | (1.71 K) | |||
| EBITDA | 631.22 K | |||
| Net Income | 759.62 K | |||
| Cash And Equivalents | 761.6 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 227.41 K | |||
| Debt To Equity | 4.65 % | |||
| Current Ratio | 0.55 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (693.58 K) | |||
| Earnings Per Share | 0.02 X | |||
| Number Of Employees | 11 | |||
| Beta | 1.55 | |||
| Market Capitalization | 2.47 M | |||
| Total Asset | 636.41 K | |||
| Z Score | 6.0 | |||
| Net Asset | 636.41 K |
About Advanced Proteome Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Advanced Proteome Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Advanced Proteome using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Advanced Proteome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Advanced Pink Sheet
Advanced Proteome financial ratios help investors to determine whether Advanced Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Advanced with respect to the benefits of owning Advanced Proteome security.